Thiazides v β-blockers | 5 | Withdrawals because of adverse effects | 31% (24 to 37) |
Low-dose thiazides v no treatment | 5 | Death | 11% (1 to 19) |
| | Stroke | 34% (21 to 44) |
| | Coronary artery disease | 29% (16 to 40) |
| | Cardiovascular events | 32% (25 to 38) |
High-dose thiazides v no treatment | 11 | Stroke | 53% (39 to 63) |
| | Cardiovascular events | 28% (18 to 37) |
Calcium-channel blockers v no treatment | 1 | Stroke | 39% (13 to 57)† |
| | Cardiovascular events | 39% (13 to 43)† |
| | |
RRI (CI)
|
ACE inhibitors v calcium-channel blockers | 1 | Withdrawals because of adverse effects | 231% (119 to 400)† |